Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)

Amylyx Pharmaceuticals' Capital Expenditures history runs 5 years deep, the most recent figure standing at $86000.0 for Q4 2025.

• On a quarterly basis, Capital Expenditures rose 330.0% year-over-year to $86000.0 in Q4 2025; TTM through Dec 2025 was $138000.0, a 12.1% decrease from a year earlier, with the FY2025 full-year figure at $138000.0, down 12.1% from the prior year.
• Capital Expenditures improved to $86000.0 in Q4 2025 per AMLX's latest filing, from $24000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.1 million in Q2 2022 and bottomed at -$19000.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $153000.0 (2021), against an average of $232368.4.
• Across the five-year window, Capital Expenditures surged 2342.86% in 2022 and sank 105.32% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $186000.0 in 2021, then jumped by 233.33% to $620000.0 in 2022, then plunged by 42.58% to $356000.0 in 2023, then slumped by 94.38% to $20000.0 in 2024, then jumped by 330.0% to $86000.0 in 2025.
• Per Business Quant, the three latest AMLX Capital Expenditures figures stand at $86000.0 (Q4 2025), $24000.0 (Q3 2025), and $17000.0 (Q2 2025).